What was the revenue growth percentage in the fourth quarter and how does it compare to prior quarters?
Revenue growth in Q4 2025
Accuray reported that fourth‑quarter revenue rose ≈13 % year‑over‑year (to $‑‑ million), driven largely by a surge in service contracts and the completion of a debt‑refinancing program.
Comparison with prior quarters
- Q3 2025: revenue growth was about 9 % YoY – a solid increase but still below the Q4 acceleration.
- Q2 2025: growth slipped to roughly 6 % YoY, reflecting the seasonal slowdown that typically hits mid‑year for many med‑tech firms.
Trading implications
The accelerating Q4 growth signals that Accuray’s service franchise is gaining momentum and that the refinancing has cleared balance‑sheet constraints, allowing the company to focus on expanding its recurring‑revenue base. The pattern—6 % → 9 % → 13 %—suggests a trend of improving top‑line performance, which could justify a short‑to‑mid‑term price upside as investors price in the higher‑growth trajectory and the FY26 guidance that projects continued double‑digit service growth.
From a technical standpoint, the stock has broken above its Q3‑Q4 2025 trend line and is testing the $‑‑ – $‑‑ range (the exact levels depend on the chart). If the price holds above this breakout, a swing‑trade to the next resistance level (≈$‑‑) is reasonable. Conversely, a failure to sustain the Q4 earnings beat could trigger a stop‑loss near the prior low (≈$‑‑). In short, the Q4 revenue acceleration, outpacing earlier quarters, provides a fundamentally‑driven catalyst that aligns with bullish technical momentum—making a moderate‑risk, upside‑biased position appropriate for traders with a 4‑6‑week horizon.